Claims
- 1. A peptide comprising a region of troponin subunit I having amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129) 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135). 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17.
- 2. The peptide of claim 1 comprising a region of troponin subunit I having amino acid residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 3. The peptide of claim 1 comprising a region of troponin subunit I having amino acid residues 132-139 (huTnI132-139) of SEQ ID NO:17.
- 4. A method of inhibiting angiogenesis associated with a disease or disorder which comprises administering an effective amount of a peptide in which the peptide is greater than 80% homology with amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of the inhibitory region of troponin subunit I (SEQ ID NO:17).
- 5. The method of claim 4 in which the peptide consists of a region of troponin subunit I having amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135) 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17.
- 6. The method of claim 5 in which the peptide consists of a region of troponin subunit I having amino acid residues 130-137 (huTnI130-137).
- 7. The method of claim 5 in which the peptide consists of a region of troponin subunit I having amino acid residues 132-139 (huTnI132-139).
- 8. The method of claim 4 in which the disease or disorder is a solid tumor.
- 9. The method of claim 8 in which the solid tumor is selected from the group consisting of sarcomas and carcinomas depicted in Table 1.
- 10. The method of claim 4 in which the disease or disorder is an ophthalmic disease or disorder.
- 11. The method of claim 4 in which the subject is a human.
- 12. The method of claim 4 in which the effective amount is about 1 to about 50 milligrams per administration.
- 13. The method of claim 4 in which the peptide is administered parenterally.
- 14. The method of claim 4 in which the peptide is administered orally.
- 15. The method of claim 4 in which the peptide is of human or bovine origin.
- 16. The method of claim 4 in which the peptide is recombinantly expressed by a cell engineered to contain a nucleotide sequence encoding said peptide.
- 17. The method of claim 4 in which the disease or disorder is lung metastases.
- 18. The method of claim 4 in which the peptide is derived from tissue.
- 19. The method of claim 18 in which the tissue is connective, muscle, nerve, or epithelial.
- 20. The method of claim 18 in which the tissue is cartilage.
- 21. A method of inhibiting angiogenesis associated with a disease or disorder which comprises administering an effective amount of a peptide having at least 8 continuous amino acid residues of the amino acid sequence selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133) 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of residues 118-137 (huTnI118-137) of SEQ ID NO:17 so that angiogenesis is inhibited.
- 22. The method of claim 21 in which the peptide consists of a region of troponin subunit I having amino acid residues 130-137 (huTnI130-137).
- 23. The method of claim 21 in which the peptide consists of a region of troponin subunit I having amino acid residues 132-139 (huTnI132-139).
- 24. The method of claim 21 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 25. The method of claim 21 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO:17.
- 26. A method of inhibiting metastasis in a mammal comprising administering an effective amount of a peptide in which the peptide is greater than 80% homology with a region of troponin subunit I selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) having amino acid residues of SEQ ID NO:17.
- 27. The method of claim 26 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 28. The method of claim 27 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO: 17.
- 29. The method of claim 26 in which the mammal is a human having a solid tumor selected from the group consisting of sarcomas and carcinomas depicted in Table 1.
- 30. The method of claim 26 in which the peptide is recombinantly expressed by a cell engineered to contain a nucleotide sequence encoding said protein.
- 31. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide in which the peptide is greater than 80% homology with amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17 and a pharmaceutically acceptable carrier.
- 32. The method of claim 31 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 33. The method of claim 31 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO:17.
- 34. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide having at least 8 continuous amino acid residues of the amino acid sequence of residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137) 132-139 (huTnI132-139) and 134-141 (huTnI134-141) of SEQ ID NO: 17.
- 35. The composition of claim 31 in which the peptide consists of the amino acid sequence of residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17.
- 36. The method of claim 35 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) or 132-139 (huTnI132-137) of SEQ ID NO:17.
- 37. The composition of claim 34 in which the peptide consists of the amino acid sequence of residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17.
- 38. The method of claim 37 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) or 132-139 (huTnI132-137) of SEQ ID NO:17.
- 39. The composition of claim 31 in which the peptide is derived from tissue.
- 40. The composition of claim 39 in which the tissue is connective, muscle, nerve, or epithelial.
- 41. The composition of claim 39 in which the tissue is cartilage.
- 42. The composition of claim 31 in which the peptide is of human or bovine origin.
- 43. The pharmaceutical composition of claim 31 or 34 in which the peptide is recombinantly expressed by a cell engineered to contain a nucleotide sequence encoding said peptide.
- 44. The method of claim 43 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) or 132-139 (huTnI132-139) of SEQ ID NO:17.
- 45. A pharmaceutical composition comprising a recombinant cell containing a nucleotide sequence encoding a peptide in which the peptide is greater than 80% homology with region of troponin subunit I having amino acid residues selected from the group consisting of 116-123 (huTnI116-123) 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17, such that said peptide is expressed in a host.
- 46. The method of claim 45 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 47. The method of claim 46 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO:17.
- 48. A pharmaceutical composition comprising a recombinant cell containing a nucleotide sequence encoding a peptide in which the peptide is a region of troponin subunit I having at least 8 continuous amino acid residues of the amino acid sequence of residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17 such that said peptide is expressed in a host.
- 49. The method of claim 48 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI132 139) of SEQ ID NO: 17.
- 50. The method of claim 49 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO: 17.
- 51. The pharmaceutical composition of claim 45 in which the peptide consists of the amino acid sequence of residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129) 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17.
- 52. The method of claim 51 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) or 132-139 (huTnI132-139) of SEQ ID NO:17.
- 53. A method for inhibiting the growth or reducing the volume of a solid tumor in a subject comprising administering a recombinant cell containing a nucleotide sequence encoding a peptide in which the peptide is greater than 80% homology with a region of troponin subunit I having amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17, such that said peptide is expressed in the host.
- 54. The method of claim 53 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 55. The method of claim 54 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO:17.
- 56. A method of inhibiting metastases in a subject comprising administering to a subject a recombinant cell containing a nucleotide sequence encoding a peptide in which the peptide is greater than 80% homology with a region of troponin subunit I having amino acid residues selected from the group consisting of 116-123 (huTnI116-123), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133). 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), and 134-141 (huTnI134-141) of SEQ ID NO:17, such that said peptide is expressed in the host.
- 57. The method of claim 56 in which the peptide consists of the amino acid sequence of residues 130-137 (huTnI130-137) of SEQ ID NO:17.
- 58. The method of claim 57 in which the peptide consists of the amino acid sequence of residues 132-139 (huTnI132-139) of SEQ ID NO:17.
Parent Case Info
[0001] This is a continuation-in-part of U.S. patent application Ser. No. 09/268,274, filed Mar. 15, 1999 which is a continuation-in-part of U.S. application Ser. No. 08/961,264, filed Oct. 30, 1997 which is a continuation of U.S. application Ser. No. 08/602,941, filed Feb. 16, 1996, now U.S. Patent No. 5,837,680.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09442099 |
Nov 1999 |
US |
Child |
10176416 |
Jun 2002 |
US |
Parent |
08602941 |
Feb 1996 |
US |
Child |
08961264 |
Oct 1997 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09268274 |
Mar 1999 |
US |
Child |
09442099 |
Nov 1999 |
US |
Parent |
08961264 |
Oct 1997 |
US |
Child |
09268274 |
Mar 1999 |
US |